Search | Clinical Trials Finder

Conditions: Endometrial Cancer, Cancer of the Endometrium
Interventions: ScaleDown, Enhanced Usual Care Packets, 12-Item Short Form Health Survey, International Physical Activity Questionnaire short form, Multidimensional Body Self Relations Questionnaire - Appearance Subscales, Cancer-Related Body Image Scale, Patient Health Questionnaire 9-Item Version, iOTA; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions: Prevention Care Management; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 64 Years · Female only
Enrollment: 2,241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Dehydration
Interventions: GENPOP ad libitum fluid intake, GENPOP fluid restriction, ATHLETE ad libitum fluid intake, ATHLETE restricted fluid intake; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 14 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Bradenton, Florida • Chicago, Illinois • Valhalla, New York + 1 more

Conditions: Contraception
Interventions: Household Visits, Small Groups, Adopt-a-Friend; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 15 Years and older
Enrollment: 3,825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT vaccine, dTpa vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years to 49 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Beaumont, Texas

Conditions: Healthy
Interventions: [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Neutropenia
Interventions: F-627, Neulasta® (pegfilgrastim); Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Anderson, Indiana

Conditions: Breast Cancer Screening
Interventions: messages; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 4,173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spasticity
Interventions: Tizanidine, Placebo, Moxifloxacin; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: everolimus, Placebo, vinorelbine, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 43
States / cities: Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more

Conditions: Gestational Diabetes
Interventions: 4000 IU vitamin D3; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Osteoporosis
Interventions: rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more

Conditions: Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions: Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control; Drug · Device · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Interstitial Lung Disease, Obstructive Sleep Apnea
Interventions: Continuous positive airway pressure (CPAP) therapy, Nox A1 Recorder; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 2,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Drug Interactions
Interventions: Fexofenadine, Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSVpreF MDV, RSVpreF SDV; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 6
States / cities: South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more

Conditions: Allergic Rhinitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control; Biological · Other
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Human Papilloma Virus, Cervical Cancer
Interventions: Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia ); Behavioral
Lead sponsor: Mark Dignan, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 4
States / cities: Hampton, Virginia • Henrico, Virginia • Richmond, Virginia

Conditions: Pelvic Floor, Perineal Rupture, Obstetric Trauma
Interventions: Not listed
Lead sponsor: Advanced Tactile Imaging, Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Princeton, New Jersey

Conditions: Dyspareunia
Interventions: Vaginal Moisturizer, Vaginal Dilator; Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: New York, New York • Providence, Rhode Island

Conditions: HIV Infections
Interventions: Raltegravir + Truvada; Drug
Lead sponsor: David A Wohl, MD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Anti Aging
Interventions: Vitality product AM + Vitality product PM, Placebo; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 35 Years to 73 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Orem, Utah

Conditions: Healthy, HIV
Interventions: Tenofovir Gel, Tenofovir Film; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Scale Down for Endometrial Cancer

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

Transdermal Optical Imaging (TOI) as a Non-invasive Measure to Detect Changes in Hydration Status in Healthy Adults and Athletes

Tipping Point: Using Social Network Theory to Accelerate Scale and Impact

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Messaging Strategies to Reduce Breast Cancer Over-screening in Older Women

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

High Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High Risk Pregnant Women

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Promise Women Project

Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions Before the Delivery

Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women

Comparison of Tenofovir Vaginal Gel and Film Formulations